Clik here to view.
GeneNews in pact for first personalized medicine center in China
GeneNews (TSX:GEN) has signed a memorandum of understanding with Shanghai Biochip, a leading Chinese engineering center for advanced microarray and gene expression profiling technologies, for a...
View ArticleGeneNews in JV; to launch ColonSentry test throughout US
GeneNews (TSX:GEN) has formed a joint venture with two private American companies, Health Diagnostic Laboratory, and a sales organization with national capabilities, to establish an accredited...
View ArticleClik here to view.
Venaxis pivotal APPY1 data due in March
Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a...
View ArticleClik here to view.
GeneNews’ IDL off to flying start
GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics...
View ArticleClik here to view.
PHI test included in updated NCCN Guidelines
Beckman Coulter’s Prostate Health Index (PHI), which is offered in the U.S. by GeneNews’ (TSX:GEN) Innovation Diagnostic Lab (IDL) joint venture, has been recommended by the National Comprehensive...
View ArticleClik here to view.
Amarantus on road to commercializing AD test
Amarantus Bioscience Holdings’ (OTCQB:AMBS) master services agreement with the lab services arm of ICON (NASDAQ:ICLR) puts Amarantus on the road to commercializing its LymPro diagnostic blood test for...
View ArticleClik here to view.
GeneNews gets promising early results from lung cancer study
GeneNews (TSX:GEN) has received encouraging early results from the largest randomized trial ever conducted for the early detection of lung cancer using EarlyCDT-Lung, an autoantibody biomarker blood...
View ArticleClik here to view.
In conversation with Geoffrey Hamilton-Fairley
Mr. Hamilton-Fairley As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the...
View Article
